Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 13, 2023 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2023 and provided a corporate update.
Related news for (KTRA)
- kintara therapeutics announces correction to prior announcement regarding 1-for-35 reverse stock split in connection with the proposed merger with tuhura biosciences to close on october 18, 2024
- kintara therapeutics announces 1-for-35 reverse stock split in connection with the proposed merger with tuhura biosciences
- kintara therapeutics announces correction to prior announcement regarding cvr issuance in connection with the proposed merger with tuhura biosciences expected to close on october 18, 2024
- kintara therapeutics announces record date for cvr issuance in connection with the proposed merger with tuhura biosciences expected to close on october 18, 2024
- kintara therapeutics announces fiscal 2024 financial results and provides corporate update